Curosurf (poractant alfa) is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. To treat premature infants requiring mechanical ventilation with clinical signs of surfactant deficiency and/or RDS confirmed by x-ray, the first dose of CUROSURF has to be administered as soon as possible, preferably within 6 hours of birth. Based on the results of clinical trials best results are obtained when CUROSURF is administered early in the course of RDS in infants with gestational age < 30 weeks or birth weight < 1500 g.

For complete prescribing information, warnings and precautions, please consult the Product Monograph.

PEYONA (caffeine citrate), 20 mg / mL solution for infusion and oral use, is indicated for the short-term treatment of primary apnea of premature newborns. Treatment must be initiated under the supervision of a physician experienced in neonatal intensive care. PEYONA is for use in Neonatal Intensive Care Units only. Measurement of baseline caffeine levels, monitoring of plasma concentrations as well as dose adjustments during therapy is advisable.

For complete prescribing information, warnings and precautions, please consult the Product Monograph.